Inflammatory myopathies

Current Treatment Options in Neurology

Volumn 13, Issue 2, 2011, Pages 119-130

  Distad, B Jane ^a   Amato, Anthony A ^b   Weiss, Michael D ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BETA1A INTERFERON; CORTICOSTEROID; CREATININE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETANERCEPT; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE SODIUM SUCCINATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OXANDROLONE; PLACEBO; PREDNISONE; RITUXIMAB; TACROLIMUS;

ABDOMINAL PAIN; ALOPECIA; ANOREXIA; ASEPTIC MENINGITIS; ASTHENIA; AVASCULAR NECROSIS; BLEEDING; BONE MARROW SUPPRESSION; CARCINOGENICITY; CATARACT; CHILL; COMBINATION CHEMOTHERAPY; CORTICOSTEROID INDUCED MYOPATHY; CYSTITIS; DERMATOMYOSITIS; DIABETES MELLITUS; DIARRHEA; DIET SUPPLEMENTATION; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTRON MICROSCOPY; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; GINGIVA HYPERPLASIA; GLAUCOMA; HEADACHE; HUMAN; HYPERTENSION; HYPERTRICHOSIS; HYPOKALEMIA; IMAGE ANALYSIS; INCLUSION BODY MYOSITIS; INFECTION SENSITIVITY; INFERTILITY; INTERSTITIAL PNEUMONIA; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LIVER TOXICITY; MONOTHERAPY; MOOD DISORDER; MORNING DOSAGE; MYALGIA; MYOSITIS; NAUSEA; NEPHROTOXICITY; OSTEOPOROSIS; PANCREATITIS; PEPTIC ULCER; PHYSIOTHERAPY; POLYMYOSITIS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PSYCHOSIS; RASH; REPEATED DRUG DOSE; RESPIRATORY TRACT DISEASE; REVIEW; SHIVERING; SIDE EFFECT; SKIN FRAGILITY; STEM CELL TRANSPLANTATION; STOMATITIS; TERATOGENICITY; TREMOR; VOMITING; WALKING AID; WEIGHT GAIN; WHEELCHAIR; WOUND HEALING IMPAIRMENT;

EID: 79955829806     PISSN: 10928480     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11940-010-0111-8     Document Type: Review

References (46)

1. Dalakas MC: Inflammatory disorders of muscle: progress in polymyositis, dermatomyositis and inclusion body myositis. Curr Opin Neurol 2004, 17:561-567.
2. Hoogendijk JE, Amato AA, Lecky BR, et al.: Workshop report. 119th ENMC international workshop: Trial: design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003. Naarden, The Netherlands. Neuromusc Dis 2004, 14:337-345. (Pubitemid 38507409)
3. Grable-Esposito P, Katzberg HD, Greenberg SA, et al.: Immune-mediated necrotizing myopathy associated with statins. Muscle Nerve 2010, 41(2):185-190.
4. Vosskamper M, Korf B, Franke B, et al.: Paraneoplastic necrotizing myopathy: a rare disorder to be differentiated form polymyositis. J Neurol 1989, 236:489-490. (Pubitemid 20019438)
5. Bronner IM, Hoogendijk JE, Wintzen AR, et al.: Necrotizing myopathy, an unusual presentation of a steroid responsive myopathy. J Neurol 2003, 250:480-485. (Pubitemid 36459756)
6. Bohan A, Peters JB: Polymyositis and dermatomyositis: part 1. N Engl J Med 1975, 292:344-347.
7. Bohan A, Peters JB: Polymyositis and dermatomyositis: part 2. N Engl J Med 1975, 292:403-407.
8. Askanas V, Serratrice G, Engel WK (eds.): Inclusion-Body Myositis and Myopathies. Cambridge, UK: Cambridge University Press; 1998.
9. Dalakas MC: Progress in inflammatory myopathies: good but not good enough. J Neurol Neurosurg Psychiatry 2001, 70:569-573.
10. Amato AA, Gronseth GS, Jackson CE, et al.: Inclusion body myositis: clinical and pathological boundaries. Ann Neurol 1995, 40:581-586.
11. Darrow DH, Hoffman HT, Barnes GJ, et al.: Management of dysphagia in inclusion body myositis. Arch Otolaryngol Head Neck Surg 1992, 118:313-317.
12. Verma A, Bradley WG, Adensina AM, et al.: Inclusion body myositis with cricopharyngeus muscle involvement and severe dysphagia. Muscle Nerve 1991, 14:470-473.
13. Kissel JT, Mendell JR, Rammohan KW: Microvascular deposition of complement membrane attack complex in dermatomyositis. N Engl J Med 1986, 314:331-334.
14. Kissel JT, Halterman RK, Rammohan KW, Mendell JR: The relationship of complement-mediated microvasculopathy to the histologic features and clinical duration of disease in dermatomyositis. Arch Neurol 1991, 48:26-30.
15. De Visser M, Emslie-Smith AM, Engel AG: Early ultrastructural alterations in adult dermatomyositis: capillary abnormalities precede other structural changes in muscle. J Neurol Sci 1989, 94:181-192. (Pubitemid 20019455)
16. Greenberg SA, Pinkus JL, Pinkus GS, et al.: Interferon-alpha/beta- mediated innate immune mechanisms in dermatomyositis. Ann Neurol 2005, 57 (5):664-678. (Pubitemid 40628855)
17. Greenberg SA, Bradshaw EM, Pinkus JL, et al.: Plasma cells in muscle in inclusion body myositis and polymyositis. Neurology 2005, 65(11):1782-1787.
18. Mendell JR, Sahenk Z, Gales T, et al.: Amyloid filaments in inclusion body myositis. Novel findings provide insight into nature of filaments. Arch Neurol 1991, 48:1229-1234.
19. Greenberg SA: Inclusion body myositis: review of recent literature. Curr Neurol Neurosci Rep 2009, 983-989. This is an excellent recent review of IBM, with a focus on its pathogenesis and an emphasis on the limitations of the evidence supporting beta-amyloid-mediated muscle injury as a cause of this disease.
20. Amato AA, Barohn RJ: Evaluation and treatment of inflammatory myopathies. J Neurol Neurosurg Psychiatry 2009, 80(10):1060-1068. This outstanding recent review summarizes the clinical and pathologic characteristics of the idiopathic inflammatory myopathies and their treatment. The authors put forth a convincing argument that our understanding of the pathogenesis of these diseases remains limited and that well designed, randomized treatment trials are lacking.
21. Bunch TW, Worthington JW, Combs JJ, et al.: Azathioprine with prednisone for polymyositis: a controlled, clinical trial. Ann Intern Med 1980, 92:365-369. (Pubitemid 10154812)
22. Bunch TW: Prednisone and azathioprine for polymyositis: long-term follow-up. Arthritis Rheum 1981, 24:45-48.
23. Dalakas MC, Illa I, Dambrosia JM, et al.: A controlled trial of high-dose intravenous immunoglobulin infusions as treatment for dermatomyositis. N Engl J Med 1993, 329:1993-2000. (Pubitemid 24015043)
24. Cherin P, Pelletier S, Teixeira A, et al.: Results and long term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients. Arthritis Rheum 2002, 46:467-474. (Pubitemid 34136585)
25. Al-Mayouf SM, Laxer RM, Schneider R, et al.: Intravenous immunoglobulin therapy for juvenile dermatomyositis: efficacy and safety. J Rheumatol 2000, 27:2498-2503.
26. Dalakas MC: Intravenous immunoglobulin in patients with anti-GAD antibody-associated neurological diseases and patients with inflammatory myopathies: effects on clinicopathological features and immunoregulatory genes. Clin Rev Allergy Immunol 2005, 29(3):255-269.
27. Qushmaq KA, Chalmers A, Esdaile JM: Cyclosporine A in the treatment of refractory adult polymyositis/dermatomyositis: population-based experience in six patients and literature review. J Rheumatol 2000, 27:2855-2859.
28. Yamasaki Y, Yamada H, Yamasaki M, et al.: Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis/dermatomyositis. Rheumatology (Oxford) 2007, 46(1):124-130. (Pubitemid 44932799)
29. Chung L, Genovese MC, Fiorentino DF: A pilot trial of rituximab in the treatment of patients with dermatomyositis. Arch Dermatol 2007, 143(6):763-767. (Pubitemid 46955736)
30. Levine TD: Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum 2005, 52:601-607.
31. Oddis CV, Reed AM, Aggarwal R, et al.: The RIM Study Group: Rituximab in the treatment of refractory adult and juvenile dermatomyositis (DM) and adult polymyositis (PM) - The RIM study. Arthritis Rheum 2010, 62:3844.
32. Barohn RJ, Amato AA, Sahenk Z, et al.: Inclusion body myositis: explanation for poor response to therapy. Neurology 1995, 45:1302-1304.
33. Joffe MM, Love LA, Leff RL: Drug therapy of idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy. Am J Med 1993, 94:379-387. (Pubitemid 23106624)
34. Leff RL, Miller FW, Hicks J, et al.: The treatment of inclusion body myositis: a retrospective review and a randomized, prospective trial of immunosuppressive therapy. Medicine 1993, 72:225-235. (Pubitemid 23246251)
35. Soueidan SA, Dalakas M: Treatment of inclusion body myositis with high-dose intravenous immunoglobulin. Neurology 1993, 43:876-879. (Pubitemid 23150554)
36. Dalakas MC, Koffman B, Fujii M, et al.: A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM. Neurology 2001, 56:323-327. (Pubitemid 32144142)
37. Dalakas MC, Sonies B, Dambrosia J, et al.: Treatment of inclusion body myositis with IVIG; a double-blind, placebo-control study. Neurology 1997, 48:712-716.
38. Walker MC, Lochmuller H, Toepfer M, et al.: High dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo controlled study. J Neurol 2000, 247:22-28. (Pubitemid 30162508)
39. Badrising UA, Maat-Schieman ML, Ferrari MD, et al.: Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo. Ann Neurol 2002, 51 (3):369-372. (Pubitemid 34206293)
40. Rutkove SB, Parker RA, Nardin RA, et al.: A pilot randomized trial of oxandrolone in inclusion body myositis. Neurology 2002, 58(7):1081-1087. (Pubitemid 34298550)
41. Lindberg C, Trysberg E, Tarkowski A, et al.: Anti-T-lymphocyte globulin treatment in inclusion body myositis: a randomized pilot study. Neurology 2003, 61(2):260-262. (Pubitemid 36875317)
42. Muscle Study Group: Randomized pilot trial of high-dose betaINF-1a in patients with inclusion body myositis. Neurology 2004, 63(4):718-720.
43. Hallengren C, Richards S, Thomas EL, et al.: Creatine supplements in patients with idiopathic inflammatory myopathies who are clinically weak after conventional pharmacologic treatment: Six-month, double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2007, 57(4):694-702. (Pubitemid 46764062)
44. DeBleecker J, Meire V, Declercq W, Van Aken E: Immunolocalization of tumor necrosis factor-alpha and its receptors in inflammatory myopathies. Neuromuscul Disord 1999, 9:239-246. (Pubitemid 29287259)
45. Hengstman GJ, De Bleecker JL, Feist E, et al.: Open-label trial of anti-TNF-alpha in dermato- and polymyositis treated concomitantly with methotrexate. Eur Neurol 2008, 59(3-4):159-163. (Pubitemid 351301260)
46. Holzer U, van Royen-Kerkhof A, van der Torre P, et al.: Successful autologous stem cell transplantation in two patients with juvenile dermatomyositis. Scand J Rheumatol 2010, 39(1):88-92.